适形调强放疗联合培门冬酶化疗治疗结外鼻型自然杀伤/T细胞淋巴瘤患者的疗效和安全性  

Efficacy and safety of intensity-modulated radiation therapy combined with pegasparaginase chemotherapy in the treatment of patients with extranodal nasal natural killer/T cell lymphoma

作　　者：李言冰 蔡玲玉 左宏波 LI Yanbing;CAI Lingyu;ZUO Hongbo(Second Department of Oncology,Jiujiang NO.1 People's Hospital,Jiujiang,Jiangxi,332000,China)

机构地区：[1]九江市第一人民医院肿瘤二科,江西九江332000

出　　处：《当代医学》2024年第36期108-112,共5页Contemporary Medicine

摘　　要：目的探究适形调强放疗(intensity modulated radiation therapy,IMRT)联合培门冬酶(pegasparaginase,PEG-ASP)化疗治疗结外鼻型自然杀伤/T细胞淋巴瘤(extranodal nasal natural killer/T cell lymphoma,ENKTCL)患者的疗效和安全性。方法选取2020年1月至2022年1月九江市第一人民医院收治的80例ENKTCL患者作为研究对象,按照随机数字表法分为常规组与研究组,各40例。常规组采用IMRT联合左旋门冬酰胺(L-asparaginase,L-ASP)化疗治疗,研究组采用IMRT联合PEG-ASP化疗治疗。比较两组临床疗效、不良反应发生情况及随访死亡率。结果治疗后,研究组治疗总有效率为87.50%,高于常规组的65.00%,差异有统计学意义(P<0.05);治疗后,研究组口腔黏膜反应、皮肤反应、口干1~2级及骨髓抑制3~4级发生率均低于常规组,骨髓抑制1~2级发生率高于常规组,差异有统计学意义(P<0.05);经随访12个月后,研究组死亡率为2.50%,低于常规组的20.00%,差异有统计学意义(P<0.05)。结论IMRT联合PEG-ASP化疗治疗ENKTCL患者疗效确切,可降低患者口腔黏膜反应、皮肤反应、口干、骨髓抑制发生率和患者死亡率,安全性较高,值得临床推广应用。Objective To investigate the efficacy and safety of intensity-modulated radiation therapy(IMRT)combined with pegasparaginase(PEG-ASP)chemotherapy in the treatment of patients with extranodal nasal natural killer/T cell lymphoma(ENKTCL).Methods 80 patients with ENKTCL admitted to Jiujiang NO.1 People's Hospital from January 2020 to January 2022 were selected as the research subjects,and they were divided into the conventional group and the study group using the random number table method,with 40 cases in each group.The conventional group was treated with IMRT combined with L-asparaginase(L-ASP)chemotherapy,while the study group was treated with IMRT combined with PEGASP chemotherapy.Clinical efficacy,adverse reactions and follow-up mortality rate were compared between the two groups.Results After treatment,the total effective rate of treatment in the study group was 87.50%,which was higher than 65.00%in the conventional group,the difference was statistically significant(P<0.05).After treatment,the incidence rate of oral mucosal reaction,skin reaction,dry mouth grade 1-2 and bone marrow suppression grade 3-4 in the study group were lower than those in the conventional group,and the incidence rate of bone marrow suppression grade 1-2 was higher than that in the conventional group,the differences were statistically significant(P<0.05).After 12 months of follow-up,the mortality rate in the study group was 2.50%,which was lower than 20.00%in the conventional group,and the difference was statistically significant(P<0.05).Conclusion IMRT combined with PEG-ASP chemotherapy is effective in treating patients with ENKTCL,it can reduce the incidence of oral mucosal reactions,skin reactions,bone marrow suppression and mortality of patients,indicating high safety,it is worthy of clinical promotion and application.

关 键 词：适形调强放疗 培门冬酶 左旋门冬酰胺 结外鼻型NKT细胞淋巴瘤 

分 类 号：R73[医药卫生—肿瘤]